# Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

> **NCT06376916** · PHASE3 · RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 153 (estimated)

## Conditions studied

- Tachycardia Atrial
- Atrial Fibrillation
- Atrial Flutter With Rapid Ventricular Response

## Interventions

- **DRUG:** Magnesium Sulfate 2 G
- **DRUG:** Magnesium Sulfate 4 G
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT06376916
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-07
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 153 (ESTIMATED)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06376916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06376916, "Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06376916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*